Bio Path | BPTH - Cash And Equivalent


Bio Path reported 13.65M in Cash and Equivalent for its fiscal quarter ending in September of 2022.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Baxter International USD 2.15B 133M Jun/2026
Bio Path 13.65M 3.37M Sep/2022
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026